IBRX CEO Reveals Fresh Anktiva Data After Bladder Cancer Trial Win — Says FDA Filing Is Just Weeks Away
ImmunityBio (IBRX) CEO Richard Adcock presented new data on Anktiva's bladder cancer trial, reporting a P-value of 0.01. The company plans to file for FDA approval within weeks. IBRX stock fell 1% to $5.98. Q3 revenue rose 53% to $48.7M, with nine-month revenue up 92% to $143.6M.
How this was made
The 30-second read
Why it matters
If the FDA accepts and approves the expansion, earlier-line use could expand the addressable patient population and improve commercial trajectory; however, the article emphasizes that full top-line numbers are still being prepared for medical congresses.
Market read
Traders get a near-term regulatory milestone window (submission in coming weeks) plus incremental trial-statistics context, which can shift expectations ahead of FDA review.
What to watch
FDA filing timing does not equal approval timing; review duration, label scope, and the strength of the full dataset presented at medical congresses could materially change expectations.
Background
ImmunityBio’s Anktiva is used with BCG for certain non-muscle-invasive bladder cancer patients, and the company is seeking a label expansion to start Anktiva alongside BCG from the outset.
Ticker impact
ImmunityBio CEO said it will submit an FDA filing in coming weeks to expand Anktiva use with first-course BCG, weeks away.
Likely upward bias as traders price in a faster path to label expansion, tempered by uncertainty around FDA review timing and statistical interpretation.
The article provides a specific timeline for filing and reiterates trial endpoint details, but it does not confirm FDA acceptance or approval.
Market effects
Reinforces momentum in bladder cancer immunotherapy combinations and the market’s focus on BCG-naive or earlier-line label expansions.
Primarily US biotech sentiment, with London conference commentary acting as a catalyst for US-listed trading.
Limited spillover beyond oncology biotech peers unless the FDA filing triggers broader read-across on similar BCG-combination strategies.
Counterpoint
The trial’s P-value and endpoint framing may not translate into a clean regulatory outcome, and the article does not provide full top-line efficacy details yet.
Key entities
- companyImmunityBio
US-listed biotech (IBRX) developing Anktiva for bladder cancer, planning an FDA filing for earlier use with BCG.
- drugAnktiva
ImmunityBio’s bladder cancer therapy intended to be used with BCG, with a proposed label expansion.
- clinical_trialQuilt-2.005 trial
Randomized trial (370 patients) where adding Anktiva to BCG met its endpoint with a reported P-value of 0.01.
- regulatorFDA
US regulator whose review of the planned filing could determine label expansion timing and scope.



